Clinical Trial

Effect of Remazolam Besylate Combined With Remifentanil Analgesic Sedation on the Prognosis of Patients With Sepsis

Enrolling by Invitation Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated April 10, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
In this study, midazolam was used as a control to investigate the effect of remazolam besylate combined with remifentanil on analgesia and sedation in patients with mechanical ventilation of sepsis on the prognosis of patients, and to provide evidence for the safe application of remazolam besylate in patients with sepsis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-09.
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-04-08
Trial Details
NCT Number NCT06731088
Lead Sponsor First Affiliated Hospital of Ningbo University
Conditions Sepsis
Enrollment 100 participants
Start Date 2025-01-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-10